Sangui Biotech International
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Sangui Biotech International generated cash of -$11,639, which is more than the previous year. Cash used in financing activities reached the amount of $0 last year. Net change in cash is therefore -$27,504.
Cash Flow
| 2014 | -760.23K | -234.63K | 924.06K |
|---|---|---|---|
| 2015 | -602.29K | 30.07K | 460.96K |
| 2016 | -394.75K | 6.94K | 428.86K |
| 2017 | -323.10K | 1 | 307.59K |
| 2018 | -253.76K | 0 | 244.60K |
| 2019 | -316.91K | 0 | 326.51K |
| 2020 | -168.38K | -3.09K | 159.18K |
| 2021 | -145.84K | 0 | 162.01K |
| 2022 | -140.45K | 0 | 142.34K |
| 2023 | -11.63K | 0 | 0 |
SGBI Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 30.46K | 29.76K | 15.28K | 27.45K | 20.94K | 56.99K | 70.07K | 17.67K | 98.14K | 47.76K |
Operating activities | ||||||||||
Net income | -147.72K | -63.34K | -203.71K | -198.52K | -342.51K | -215.80K | -329.60K | -446.36K | -758.40K | -1.57M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 14.09K | 21.50K | -18.28K | -10.69K | 0 | 0 | 0 | 50K | 0 | 468 |
Stock-based compensation expense | 0 | 0 | 0 | 6.71K | 18.65K | 0 | 9.62K | 0 | 52.42K | 302.35K |
| Deferred income tax benefit | 0 | 0 | 0 | 6.71K | 18.65K | 0 | 9.62K | 0 | 52.42K | 302.35K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -14.12K | 1.50K | -6.77K | 19.43K | 18.41K | -48.62K | 48 | -6.98K | 1.68K | -2.71K |
Inventories | 0 | 0 | 22.63K | 11.70K | 8.08K | 5.39K | 268.73K | 164.53K | 502.58K | -17.08K |
Accounts payable | 0 | 29.53K | 23.91K | 8.37K | -13.96K | 5.61K | -14.54K | 69.68K | -14.33K | -73.98K |
Cash generated by operating activities | -11.63K | -140.45K | -145.84K | -168.38K | -316.91K | -253.76K | -323.10K | -394.75K | -602.29K | -760.23K |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | -3.09K | 0 | 0 | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -241.46K |
Cash generated by investing activities | 0 | 0 | 0 | -3.09K | 0 | 0 | 1 | 6.94K | 30.07K | -234.63K |
Financing activities | ||||||||||
Common Stock Issued | 0 | 28.34K | 60.5K | 15.41K | 84.49K | 154.48K | 307.59K | 432.95K | 319.50K | 942.92K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 67.55K | -101.51K | -143.76K | 0 | 0 | 0 | -26.3K | 0 | -18.86K |
Cash used in financing activities | 0 | 142.34K | 162.01K | 159.18K | 326.51K | 244.60K | 307.59K | 428.86K | 460.96K | 924.06K |
Net Change In Cash | -27.50K | 701 | 14.48K | -12.17K | 6.51K | -36.04K | -13.08K | 52.40K | -80.47K | 50.38K |
Cash at end of period | 2.96K | 30.46K | 29.76K | 15.28K | 27.45K | 20.94K | 56.99K | 70.07K | 17.67K | 98.14K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |